stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
34.81
2.28
+7.01%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Shares outstanding
Pharvaris N.V.'s shares outstanding at the end of fiscal 2025 was $59.2M, up 9.51% from $54.0M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $68.1M. Over the past ten years it has ranged from $4.9M (fiscal 2020) to $59.2M (fiscal 2025) — the current reading is the highest in ten years. Pharvaris N.V. ranks 222nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $59.2M | 9.51% |
| FY2024 | $54.0M | 40.71% |
| FY2023 | $38.4M | 14.31% |
| FY2022 | $33.6M | 10.44% |
| FY2021 | $30.4M | 527.05% |
| FY2020 | $4.9M | 0.00% |
| FY2019 | $4.9M | 0.00% |
| FY2018 | $4.9M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $68.1M | 4.24% |
| Mar 2026 | $65.3M | 10.39% |
| Dec 2025 | $59.2M | (4.97%) |
| Sep 2025 | $62.3M | 13.84% |
| 19 more quarters | Free account |
Against its own ten years
Low $4.9M
High $59.2M
Ten-year median
$32.0M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| PHVS Pharvaris N.V. | $68.1M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item